Combination Therapy of Angiotensin II Receptor Blocker and Calcium Channel Blocker Exerts Pleiotropic Therapeutic Effects in Addition to Blood Pressure Lowering: Amlodipine and Candesartan Trial in Yokohama (ACTY)

REFERENCES

• Dahlof B, Devereux RB, Kjeldsen SE, . Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:995–1003.
   PubMed Web of Science ®Google Scholar
• Casas JP, Chua W, Loukogeorgakis S, . Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 2005; 366:2026–2033.
   PubMed Web of Science ®Google Scholar
• Jamerson K, Weber MA, Bakris GL, . Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359:2417–2428.
   PubMed Web of Science ®Google Scholar
• Ogihara T, Kikuchi K, Matsuoka H, . Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res 2009; 32:3–107.
   PubMed Web of Science ®Google Scholar
• Ishimitsu T, Numabe A, Masuda T, . Angiotensin-II receptor antagonist combined with calcium channel blocker or diuretic for essential hypertension. Hypertens Res 2009; 32:962–968.
   PubMed Web of Science ®Google Scholar
• Coleman A, Freeman P, Steel S, Shennan A. Validation of the Omron 705IT (HEM-759-E) oscillometric blood pressure monitoring device according to the British Hypertension Society protocol. Blood Press Monit 2006; 11:27–32.
   PubMed Web of Science ®Google Scholar
• Takazawa K, Kobayashi H, Shindo N, Tanaka N, Yamashina A. Relationship between radial and central arterial pulse wave and evaluation of central aortic pressure using the radial arterial pulse wave. Hypertens Res 2007; 30:219–228.
   PubMed Web of Science ®Google Scholar
• Kips JG, Schutte AE, Vermeersch SJ, . Comparison of central pressure estimates obtained from SphygmoCor, Omron HEM-9000AI and carotid applanation tonometry. J Hypertens 2011; 29:1115–1120.
   PubMed Web of Science ®Google Scholar
• Rezai MR, Goudot G, Winters C, Finn JD, Wu FC, Cruickshank JK. Calibration mode influences central blood pressure differences between SphygmoCor and two newer devices, the arteriograph and Omron HEM-9000. Hypertens Res 2011; 34:1046–1051.
   PubMed Web of Science ®Google Scholar
• Tomiyama H, Odaira M, Matsumoto C, . Effects of moderate-to-severe impairment of the estimated glomerular filtration rate and of proteinuria on the central hemodynamics and arterial stiffness in middle-aged healthy Japanese men. Int J Nephrol 2011; 2011:427471.
   PubMedGoogle Scholar
• Yamashina A, Tomiyama H, Takeda K, . Validity, reproducibility, and clinical significance of noninvasive brachial-ankle pulse wave velocity measurement. Hypertens Res 2002; 25: 359–364.
   PubMed Web of Science ®Google Scholar
• Masuda S, Tamura K, Wakui H, . Effects of angiotensin II type 1 receptor blocker on ambulatory blood pressure variability in hypertensive patients with overt diabetic nephropathy. Hypertens Res 2009; 32:950–955.
   PubMed Web of Science ®Google Scholar
• Mitsuhashi H, Tamura K, Yamauchi J, . Effect of losartan on ambulatory short-term blood pressure variability and cardiovascular remodeling in hypertensive patients on hemodialysis. Atherosclerosis 2009; 207:186–190.
   PubMed Web of Science ®Google Scholar
• Ogihara T, Nakao K, Fukui T, . Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial. Hypertension 2008; 51:393–398.
   PubMed Web of Science ®Google Scholar
• Uzu T, Sawaguchi M, Maegawa H, Kashiwagi A. Reduction of microalbuminuria in patients with type 2 diabetes: the Shiga Microalbuminuria Reduction Trial (SMART). Diabetes Care 2007; 30:1581–1583.
   PubMed Web of Science ®Google Scholar
• Julius S, Kjeldsen SE, Weber M, . Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363:2022–2031.
   PubMed Web of Science ®Google Scholar
• Kaneshiro Y, Ichihara A, Sakoda M, Kurauchi-Mito A, Kinouchi K, Itoh H. Add-on benefits of amlodipine and thiazide in nondiabetic chronic kidney disease stage 1/2 patients treated with valsartan. Kidney Blood Press Res 2009; 32:51–58.
   PubMed Web of Science ®Google Scholar
• Bakris GL, Sarafidis PA, Weir MR, . Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet 2010; 375:1173–1181.
   PubMed Web of Science ®Google Scholar
• Matsushita K, van der Velde M, Astor BC, . Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010; 375:2073–2081.
   PubMed Web of Science ®Google Scholar
• Herzog CA, Asinger RW, Berger AK, Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2011; 80:572–586.
   PubMed Web of Science ®Google Scholar
• Ichihara A, Kaneshiro Y, Sakoda M, Takemitsu T, Itoh H. Add-on amlodipine improves arterial function and structure in hypertensive patients treated with an angiotensin receptor blocker. J Cardiovasc Pharmacol. 2007; 49:161–166.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Agnoletti D, Safar ME, Blacher J. Effect of antihypertensive agents on blood pressure variability: the natrilix SR versus candesartan and amlodipine in the reduction of systolic blood pressure in hypertensive patients (X-CELLENT) study. Hypertension 2011; 58:155–160.
   PubMed Web of Science ®Google Scholar
• Parati G, Di Rienzo M, Mancia G. Neural cardiovascular regulation and 24-hour blood pressure and heart rate variability. Ann NY Acad Sci 1996; 783:47–63.
   PubMed Web of Science ®Google Scholar
• Tamura K, Tsurumi Y, Sakai M, . A possible relationship of nocturnal blood pressure variability with coronary artery disease in diabetic nephropathy. Clin Exp Hypertens 2007; 29:31–42.
   PubMed Web of Science ®Google Scholar
• Eto M, Toba K, Akishita M, . Reduced endothelial vasomotor function and enhanced neointimal formation after vascular injury in a rat model of blood pressure lability. Hypertens Res 2003; 26:991–998.
   PubMed Web of Science ®Google Scholar
• Kudo H, Kai H, Kajimoto H, . Exaggerated blood pressure variability superimposed on hypertension aggravates cardiac remodeling in rats via angiotensin II system-mediated chronic inflammation. Hypertension 2009; 54:832–838.
   PubMed Web of Science ®Google Scholar
• Eguchi K, Ishikawa J, Hoshide S, . Night time blood pressure variability is a strong predictor for cardiovascular events in patients with type 2 diabetes. Am J Hypertens 2009; 22:46–51.
   PubMed Web of Science ®Google Scholar
• Ozawa M, Tamura K, Okano Y, . Blood pressure variability as well as blood pressure level is important for left ventricular hypertrophy and brachial-ankle pulse wave velocity in hypertensives. Clin Exp Hypertens 2009; 31:669–679.
   PubMed Web of Science ®Google Scholar
• Shigenaga A, Tamura K, Dejima T, . Effects of angiotensin II type 1 receptor blocker on blood pressure variability and cardiovascular remodeling in hypertensive patients on chronic peritoneal dialysis. Nephron Clin Pract 2009; 112:c31–c40.
   PubMed Web of Science ®Google Scholar
• Shintani Y, Kikuya M, Hara A, . Ambulatory blood pressure, blood pressure variability and the prevalence of carotid artery alteration: the Ohasama study. J Hypertens 2007; 25:1704–1710.
   PubMed Web of Science ®Google Scholar
• Kanaoka T, Tamura K, Moriya T, . Effects of multiple factorial intervention on ambulatory BP profile and renal function in hypertensive type 2 diabetic patients with overt nephropathy—a pilot study. Clin Exp Hypertens 2011; 33:255–263.
   PubMed Web of Science ®Google Scholar
• Kikuya M, Hozawa A, Ohokubo T, . Prognostic significance of blood pressure and heart rate variabilities: the Ohasama study. Hypertension 2000; 36:901–906.
   PubMed Web of Science ®Google Scholar
• Eto M, Toba K, Akishita M, . Impact of blood pressure variability on cardiovascular events in elderly patients with hypertension. Hypertens Res 2005; 28:1–7.
   PubMed Web of Science ®Google Scholar
• Kikuya M, Ohkubo T, Metoki H, . Day-by-day variability of blood pressure and heart rate at home as a novel predictor of prognosis: the Ohasama study. Hypertension 2008; 52:1045–1050.
   PubMed Web of Science ®Google Scholar
• Webb AJ, Fischer U, Mehta Z, Rothwell PM. Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis. Lancet 2010; 375:906–915.
   PubMed Web of Science ®Google Scholar
• Rothwell PM, Howard SC, Dolan E, . Effects of beta blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke. Lancet Neurol 2010; 9:469–480.
   PubMed Web of Science ®Google Scholar
• Ushigome E, Fukui M, Hamaguchi M, The coefficient variation of home blood pressure is a novel factor associated with macroalbuminuria in type 2 diabetes mellitus. Hypertens Res 2011; 34:1271–1275.
   Google Scholar
• Manios E, Stamatelopoulos K, Tsivgoulis G, . Time rate of blood pressure variation: a new factor associated with coronary atherosclerosis. J Hypertens 2011; 29:1109–1114.
   PubMed Web of Science ®Google Scholar
• Bilo G, Parati G. Rate of blood pressure changes assessed by 24 h ambulatory blood pressure monitoring: another meaningful index of blood pressure variability? J Hypertens 2011; 29:1054–1058.
   PubMed Web of Science ®Google Scholar
• Tamura K, Azushima K, Umemura S. Day-by-day home-measured blood pressure variability: another important factor in hypertension with diabetic nephropathy? Hypertens Res 2011; 34:1249–1250.
   Google Scholar
• Iwai M, Li HS, Chen R, . Calcium channel blocker azelnidipine reduces glucose intolerance in diabetic mice via different mechanism than angiotensin receptor blocker olmesartan. J Pharmacol Exp Ther 2006; 319:1081–1087.
   PubMed Web of Science ®Google Scholar
• Matsui Y, Eguchi K, O’Rourke MF, . Differential effects between a calcium channel blocker and a diuretic when used in combination with angiotensin II receptor blocker on central aortic pressure in hypertensive patients. Hypertension 2009; 54:716–723.
   PubMed Web of Science ®Google Scholar
• Matsui Y, Eguchi K, Ishikawa J, Shimada K, Kario K. Urinary albumin excretion during angiotensin II receptor blockade: comparison of combination treatment with a diuretic or a calcium-channel blocker. Am J Hypertens 2011; 24:466–473.
   PubMed Web of Science ®Google Scholar
• Tamura K, Kanaoka T, Ohsawa M, Emerging concept of anti-hypertensive therapy based on ambulatory blood pressure profile in chronic kidney disease. Am J Cardiovasc Dis 2011; 1:236–243.
   Google Scholar